Dimethylarginine Dimethylaminohydrolase 2 (DDAH 2) Gene Polymorphism, Asymmetric Dimethylarginine (ADMA) Concentrations, and Risk of Coronary Artery Disease: A Case-Control Study.
Asymmetric dimethylarginine (ADMA) has been shown to be an independent predictor of cardiovascular diseases. Dimethylarginine dimethylaminohydrolase 2 (DDAH 2) promotes the metabolism of ADMA and plays a key role in the regulation of acute inflammatory response. With the present study, we investigated the relationship between DDAH 2 polymorphisms and risk of coronary artery disease (CAD) and its association to plasma ADMA concentrations. We used the haplotype-tagging SNP approach to identify tag SNPs in DDAH 2. The SNPs were genotyped by PCR and sequenced in 385 CAD patients and 353 healthy controls. Plasma concentrations of ADMA were determined using enzyme-linked immunosorbent assay (ELISA). A promoter polymorphism -449C/G (rs805305) in DDAH 2 was identified. Compared with the ADMA concentrations in CC genotype (0.328 ± 0.077 μmol/l), ADMA concentrations in CG + GG genotype were significantly increased (0.517 ± 0.090 μmol/l, P < 0.001). No significant associations between the -449C/G and risk of CAD were detected in the genetic models. The results of this study suggest that Genetic -499C/G polymorphism in DDAH 2 gene may affect the plasma ADMA concentrations in patients with CAD. However, it does not indicate a novel genetic risk marker for CAD.
Department of Clinical Laboratory, The Affiliated Hospital of Qingdao University, Qingdao, China.
Chao
C
Xuan
Department of Clinical Laboratory, The Affiliated Hospital of Qingdao University, Qingdao, China.
Long-Qiang
LQ
Xu
Department of Clinical Laboratory, The Affiliated Hospital of Qingdao University, Qingdao, China.
Qing-Wu
QW
Tian
Department of Clinical Laboratory, The Affiliated Hospital of Qingdao University, Qingdao, China.
Hui
H
Li
Department of Clinical Laboratory, The Affiliated Hospital of Qingdao University, Qingdao, China.
Qing
Q
Wang
Department of Surgery, TEDA International Cardiovascular Hospital, Tianjin &The Affiliated Hospital of Hangzhou Normal University, Hangzhou, China.|Department of Surgery, Oregon Health and Science University, Portland, Oregon.
Guo-Wei
GW
He
Department of Clinical Laboratory, The Affiliated Hospital of Qingdao University, Qingdao, China.
Li-Min
LM
Lun
Diabetes Care. 2007 Jul;30(7):1834-9
17456842
Clin Sci (Lond). 2009 Aug 17;117(7):273-9
19250061
Arch Med Res. 2011 Nov;42(8):677-85
22154679
Ann Hum Genet. 2013 May;77(3):191-203
23438410
Sci Rep. 2014 Dec 04;4:7311
25472587
Blood. 1996 Nov 1;88(9):3528-34
8896420
Nature. 1995 May 4;375(6526):68-73
7536899
J Thorac Cardiovasc Surg. 2012 Sep;144(3):697-703
22336756
Crit Care. 2006;10 (5):R139
17002794
Eur Heart J. 2009 May;30(9):1142-50
19297385
Circ Res. 2007 Sep 14;101(6):627-35
17673667
Atherosclerosis. 2007 Mar;191(1):211-9
16828780
J Diabetes Complications. 2012 May-Jun;26(3):195-8
22521321
Br J Pharmacol. 2011 Sep;164(2):213-23
21198553
J Cardiovasc Pharmacol. 1992;20 Suppl 12:S60-2
1282988
Am J Physiol Heart Circ Physiol. 2007 Dec;293(6):H3227-45
17933965
PLoS One. 2012;7(3):e33355
22428028
Genomics. 2000 Aug 15;68(1):101-5
10950934
Arterioscler Thromb Vasc Biol. 2003 Aug 1;23 (8):1455-9
12805079
Pharmacol Res. 2009 Dec;60(6):461-5
19682581
In Vivo. 2009 Sep-Oct;23(5):797-812
19779116
Eur J Prev Cardiol. 2016 Mar;23 (5):502-10
25956428
Sci Rep. 2015 Jun 05;5:10987
26046576
Sci Rep. 2015 May 13;5:9902
25970700
Vasc Med. 2005 Jul;10 Suppl 1:S27-33
16444866
Diabetologia. 2002 Dec;45(12 ):1609-16
12488950
Lipids Health Dis. 2015 Dec 30;14:167
26718096
Diabetes Res Clin Pract. 2012 Oct;98(1):125-31
22579530
J Genet. 2011 Apr;90(1):161-3
21677405
PLoS One. 2010 Mar 01;5(3):e9462
20209122
Am J Kidney Dis. 2010 Jun;55(6):1050-9
20189274
Mol Med Rep. 2012 Nov;6(5):1103-6
22923027
Arterioscler Thromb Vasc Biol. 2006 Nov;26(11):2536-40
16931791
Atheroscler Suppl. 2003 Dec;4(4):33-40
14664901
Arterioscler Thromb Vasc Biol. 2007 Sep;27(9):2037-42
17569878